ARCHIVES

FDA Approves Lilly’s Alimta For Metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 27 No. 8 | August 27, 2004

Download PDF Visit The Full Archive

Related Articles

Drug Development Gets Extra $500,000

November 18, 1977

Mass. Requires Coverage of Routine Patient Care In Clinical Trials

September 6, 2002

President’s Cancer Panel Seeks Ways to Open Grants For More New Ideas

December 19, 1980

DCT Board Approves Concept Of Planning Grants For New Particle Therapy Equipment Development

August 7, 1981

Spartanburg CCOP Makes the List

April 10, 1987

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

November 29, 2013